ARCHIVES

FASEB Seeks $27.3B For NIH, Increases For Research, Training, And Infrastructure.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006

New Drugs Improve Outlook For Bone Marrow Cancer

March 31, 2006

Centers Subcommittee Kills Guidelines Proposal, Suggest Formula Ceiling On Core Grants

January 6, 1978

Obituary: Edwin Fisher, NSABP Pathologist.

April 4, 2008

NCAB To Seek Changes In Cancer Act Renewal, Budget Improvements

November 20, 1987

In Brief: Megastrol Acetate Still Under FDA Review; Mays Hired For NCI’s Technology Office

July 20, 1990